Clinical Trial

An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency

Study acronym: Continuation
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 \[NCT03701568\] or who were receiving nucleos(t)ide treatment and were approved by the Sponsor.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-04-14
Trial Details
NCT Number NCT03845712
Lead Sponsor UCB BIOSCIENCES, Inc.
Conditions Thymidine Kinase 2 Deficiency
Enrollment 47 participants
Start Date 2019-07-05
Primary Completion 2026-08-14 (estimated)
Study Completion 2026-08-14 (estimated)
Updated on ClinicalTrials.gov 2026-08-14